Article
Obstetrics & Gynecology
Gary Peltz, Lauren M. Jansson, Susan Adeniyi-Jones, Carol Cohane, David Drover, Steven Shafer, Meiyue Wang, Manhong Wu, Balaji Govindaswami, Priya Jegatheesan, Cynthia Argani, Salwa Khan, Walter K. Kraft
Summary: Ondansetron treatment reduces the severity of symptoms in neonatal opioid withdrawal syndrome (NOWS) and may indicate a shortened length of stay.
JOURNAL OF PERINATOLOGY
(2023)
Review
Clinical Neurology
Ying-Ying Zhang, Rong Zhou, Wan-Jie Gu
Summary: The meta-analysis results indicate that methylnaltrexone is effective and safe in alleviating opioid-induced constipation, but caution should be taken regarding the safety of abdominal pain.
Review
Pharmacology & Pharmacy
Taraneh Mousavi, Shekoufeh Nikfar, Mohammad Abdollahi
Summary: With the rise in aging population and chronic diseases, the use and abuse of opioids have increased worldwide, leading to an increase in opioid-related adverse events, specifically opioid-induced bowel dysfunction. This calls for a rational clinical management strategy.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Ehsan A. Habeeb, Lena K. Tran, Melanie Z. Goodberlet, Kenneth E. Lupi, Jeremy R. DeGrado, Kevin M. Dube
Summary: This study aimed to evaluate the efficacy of enteral naloxone (NLX) versus subcutaneous methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in critically ill patients. The results showed that NLX had a shorter time to first bowel movement compared to MNTX. Both NLX and MNTX were effective in treating OIC without causing reversal of analgesia. Future controlled trials are needed to further validate these findings.
ANNALS OF PHARMACOTHERAPY
(2023)
Article
Medicine, Research & Experimental
W. Frank Peacock, Neal Slatkin, Patrick Gagnon-Sanschagrin, Jessica Maitland, Annie Guerin, George Joseph
Summary: Patients receiving OIC-Rx in the ED had decreased odds of hospitalization and fewer re-encounters in the 30-day post-discharge period, resulting in cost savings for insurance agencies and healthcare providers.
ADVANCES IN THERAPY
(2022)
Article
Gastroenterology & Hepatology
You-Min Lin, Yanbo Tang, Yu Fu, Shrilakshmi Hegde, W. Daniel Shi, M. Li-Yen Huang, Xuan-Zheng Shi
Summary: Constipation and abdominal pain in opioid-induced bowel dysfunction may be caused by fecal retention, which leads to changes in smooth muscle function and neuronal excitability. Prevention of fecal retention through liquid diet can potentially improve symptoms by regulating the expression of COX-2 and NGF.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
(2021)
Article
Anesthesiology
Lynn R. Webster, Darren Brenner, Robert J. Israel, Nancy Stambler, Neal E. Slatkin
Summary: Methylnaltrexone may confer survival benefits in patients with opioid-induced bowel disorders taking opioids for cancer-related or chronic noncancer pain.
Article
Geriatrics & Gerontology
Solomon S. Liao, Neal E. Slatkin, Nancy Stambler
Summary: The study found that methylnaltrexone did not compromise opioid analgesia in older adults and was effective in relieving constipation with minimal side effects, regardless of age. Further research is needed to explore the impact of other factors on the safety and efficacy of methylnaltrexone.
Article
Clinical Neurology
Eric D. Shah, Bruce H. Chamberlain, Michelle Rhiner, Neil E. Slatkin, Nancy Stambler, Robert J. Israel
Summary: This study evaluated the efficacy and safety of subcutaneous methylnaltrexone for opioid-induced constipation in patients with and without active cancer. The results showed that a significantly higher proportion of patients treated with methylnaltrexone achieved a laxation response within 4 hours compared to placebo. The drug was well-tolerated and did not cause significant differences in pain scores. Therefore, subcutaneous methylnaltrexone is an effective and safe treatment for opioid-induced constipation.
JOURNAL OF PAIN RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Jeff Liang, Christopher V. Almario, William D. Chey, Carolyn S. Higgins, Brennan M. R. Spiegel
Summary: In this study of a nationally representative data set in the United States, the prevalence, symptom severity, and medication use in individuals with Rome IV chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), and opioid-exacerbated constipation (OEC) were assessed. The results showed that OIC and OEC were less prevalent than CIC, but individuals with OIC and OEC had more severe constipation symptoms and were more likely to use prescription medication.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Clinical Neurology
Neel Mehta, Neal E. Slatkin, Robert J. Israel, Nancy Stambler, Eric D. Shah
Summary: This study evaluated the safety and efficacy of methylnaltrexone in constipated patients and found that methylnaltrexone significantly improved rescue-free laxation. Abdominal pain was more common in patients receiving methylnaltrexone.
JOURNAL OF PAIN RESEARCH
(2023)
Article
Clinical Neurology
Bruce H. Chamberlain, Michelle Rhiner, Neal E. Slatkin, Nancy Stambler, Robert J. Israel
Summary: Methylnaltrexone effectively reduces constipation time in advanced illness patients, regardless of active cancer status, while preserving pain control with opioid treatment.
JOURNAL OF PAIN RESEARCH
(2021)
Article
Multidisciplinary Sciences
Md Tariqul Haque Tuhin, Dengpan Liang, Fang Liu, Hala Aldawod, Toufiq Ul Amin, Joshua S. Ho, Rasha Emara, Arjun D. Patel, Melanie A. Felmlee, Miki S. Park, James A. Uchizono, Mamoun M. Alhamadsheh
Summary: The study develops a drug delivery approach to limit the passage of small molecules across the blood-brain barrier, and also develops new potent analgesics that have a significant impact on the central nervous system.
NATURE COMMUNICATIONS
(2022)
Review
Gastroenterology & Hepatology
Karim Chamie, Vishnukamal Golla, Andrew T. Lenis, Patrick M. Lec, Siamak Rahman, Eugene R. Viscusi
Summary: PAMORAs, as peripherally acting mu-opioid receptor antagonists, have the potential to alleviate postoperative ileus and opioid-induced constipation by blocking peripheral effects of opioids in the gastrointestinal tract while maintaining their analgesic properties in the central nervous system. Further research is needed to explore the therapeutic potential of PAMORAs in the management of POI and postoperative OIC.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Chemistry, Medicinal
Boshi Huang, Mengchu Li, Pornprom Klongkumnuankarn, Rolando E. Mendez, James C. Gillespie, David L. Stevens, William L. Dewey, Dana E. Selley, Yan Zhang
Summary: Opioid-induced constipation (OIC) is a common side effect of opioid analgesics. Peripherally acting mu opioid receptor antagonists (PAMORAs) can effectively treat OIC without affecting the analgesic effects. A new compound has shown promising results in improving intestinal motility and may be developed as an oral treatment for constipation.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
